Back to top

oncology-screening: Archive

Zacks Equity Research

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

BMYPositive Net Change BNTXPositive Net Change CVACPositive Net Change IMCRPositive Net Change

Ahan Chakraborty

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change VERVNegative Net Change

Zacks Equity Research

Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.

BAYRYNegative Net Change QGENPositive Net Change INCYPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

TEVAPositive Net Change BAYRYNegative Net Change AGENNegative Net Change IMCRPositive Net Change